Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging

Deng Shun Wang, Richard B. Lipton, Mindy Joy Katz, Peter Davies, Herman Buschke, Gail Kuslansky, Joe Verghese, Steven G. Younkin, Chris Eckman, Dennis W. Dickson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Although evidence suggests that extensive cortical β-amyloid (Aβ) deposition is essential in Alzheimer disease (AD), it is also detected in nondemented elderly individuals with pathologic aging (PA). Given evidence that neutral endopeptidase (NEP) or neprilysin, a key enzyme for clearance of Aβ, is decreased in AD, the goal of the present study was to determine if NEP was also decreased in PA. We measured NEP immunoreactivity in frontal cortex of 12 AD and six PA cases and compared this with 10 normal (N) elderly individuals. None had any significant other pathology, and they were similar with respect to age, sex, and postmortem delay. In addition, Aβ1-40 and Aβ1-42 were measured by enzyme-linked immunosorbent assay (ELISA), whereas tau, synaptophysin, and α-synuclein were measured on Western blots. The AD cases had more neuritic plaques, neurofibrillary tangles, higher Braak stage, and more tau immunoreactivity in frontal cortex than both PA and N. In contrast, both PA and AD had more senile plaques and Aβ1-42 than N. NEP immunoreactivity was decreased in AD but not in PA. The decrease was unlikely the result of neuronal or synaptic loss because NEP immunoreactivity in frontotemporal degeneration with comparable degrees of synaptic loss as the AD cases was not different from control subjects. Although NEP enzyme activity was decreased in approximately half the AD cases, on average, it was not decreased compared with N or PA. The results add further evidence that PA is distinct from AD and indicate that decreased Aβ degradation by NEP is unlikely to contribute significantly to amyloid deposition in PA or, in many cases, of AD.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalJournal of Neuropathology and Experimental Neurology
Volume64
Issue number5
StatePublished - May 2005

Fingerprint

Neprilysin
Alzheimer Disease
Amyloid Plaques
Frontal Lobe
Amyloid
Synucleins
Synaptophysin
Neurofibrillary Tangles
Enzymes
Western Blotting
Enzyme-Linked Immunosorbent Assay
Pathology

Keywords

  • Alzheimer disease
  • Amyloid
  • Neprilysin
  • Neurofibrillary tangles
  • Pathological aging
  • Senile plaques
  • Synaptic markers
  • Tau

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. / Wang, Deng Shun; Lipton, Richard B.; Katz, Mindy Joy; Davies, Peter; Buschke, Herman; Kuslansky, Gail; Verghese, Joe; Younkin, Steven G.; Eckman, Chris; Dickson, Dennis W.

In: Journal of Neuropathology and Experimental Neurology, Vol. 64, No. 5, 05.2005, p. 378-385.

Research output: Contribution to journalArticle

Wang, Deng Shun ; Lipton, Richard B. ; Katz, Mindy Joy ; Davies, Peter ; Buschke, Herman ; Kuslansky, Gail ; Verghese, Joe ; Younkin, Steven G. ; Eckman, Chris ; Dickson, Dennis W. / Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. In: Journal of Neuropathology and Experimental Neurology. 2005 ; Vol. 64, No. 5. pp. 378-385.
@article{0df3ad4039804ebba44a8da698d9f432,
title = "Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging",
abstract = "Although evidence suggests that extensive cortical β-amyloid (Aβ) deposition is essential in Alzheimer disease (AD), it is also detected in nondemented elderly individuals with pathologic aging (PA). Given evidence that neutral endopeptidase (NEP) or neprilysin, a key enzyme for clearance of Aβ, is decreased in AD, the goal of the present study was to determine if NEP was also decreased in PA. We measured NEP immunoreactivity in frontal cortex of 12 AD and six PA cases and compared this with 10 normal (N) elderly individuals. None had any significant other pathology, and they were similar with respect to age, sex, and postmortem delay. In addition, Aβ1-40 and Aβ1-42 were measured by enzyme-linked immunosorbent assay (ELISA), whereas tau, synaptophysin, and α-synuclein were measured on Western blots. The AD cases had more neuritic plaques, neurofibrillary tangles, higher Braak stage, and more tau immunoreactivity in frontal cortex than both PA and N. In contrast, both PA and AD had more senile plaques and Aβ1-42 than N. NEP immunoreactivity was decreased in AD but not in PA. The decrease was unlikely the result of neuronal or synaptic loss because NEP immunoreactivity in frontotemporal degeneration with comparable degrees of synaptic loss as the AD cases was not different from control subjects. Although NEP enzyme activity was decreased in approximately half the AD cases, on average, it was not decreased compared with N or PA. The results add further evidence that PA is distinct from AD and indicate that decreased Aβ degradation by NEP is unlikely to contribute significantly to amyloid deposition in PA or, in many cases, of AD.",
keywords = "Alzheimer disease, Amyloid, Neprilysin, Neurofibrillary tangles, Pathological aging, Senile plaques, Synaptic markers, Tau",
author = "Wang, {Deng Shun} and Lipton, {Richard B.} and Katz, {Mindy Joy} and Peter Davies and Herman Buschke and Gail Kuslansky and Joe Verghese and Younkin, {Steven G.} and Chris Eckman and Dickson, {Dennis W.}",
year = "2005",
month = "5",
language = "English (US)",
volume = "64",
pages = "378--385",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging

AU - Wang, Deng Shun

AU - Lipton, Richard B.

AU - Katz, Mindy Joy

AU - Davies, Peter

AU - Buschke, Herman

AU - Kuslansky, Gail

AU - Verghese, Joe

AU - Younkin, Steven G.

AU - Eckman, Chris

AU - Dickson, Dennis W.

PY - 2005/5

Y1 - 2005/5

N2 - Although evidence suggests that extensive cortical β-amyloid (Aβ) deposition is essential in Alzheimer disease (AD), it is also detected in nondemented elderly individuals with pathologic aging (PA). Given evidence that neutral endopeptidase (NEP) or neprilysin, a key enzyme for clearance of Aβ, is decreased in AD, the goal of the present study was to determine if NEP was also decreased in PA. We measured NEP immunoreactivity in frontal cortex of 12 AD and six PA cases and compared this with 10 normal (N) elderly individuals. None had any significant other pathology, and they were similar with respect to age, sex, and postmortem delay. In addition, Aβ1-40 and Aβ1-42 were measured by enzyme-linked immunosorbent assay (ELISA), whereas tau, synaptophysin, and α-synuclein were measured on Western blots. The AD cases had more neuritic plaques, neurofibrillary tangles, higher Braak stage, and more tau immunoreactivity in frontal cortex than both PA and N. In contrast, both PA and AD had more senile plaques and Aβ1-42 than N. NEP immunoreactivity was decreased in AD but not in PA. The decrease was unlikely the result of neuronal or synaptic loss because NEP immunoreactivity in frontotemporal degeneration with comparable degrees of synaptic loss as the AD cases was not different from control subjects. Although NEP enzyme activity was decreased in approximately half the AD cases, on average, it was not decreased compared with N or PA. The results add further evidence that PA is distinct from AD and indicate that decreased Aβ degradation by NEP is unlikely to contribute significantly to amyloid deposition in PA or, in many cases, of AD.

AB - Although evidence suggests that extensive cortical β-amyloid (Aβ) deposition is essential in Alzheimer disease (AD), it is also detected in nondemented elderly individuals with pathologic aging (PA). Given evidence that neutral endopeptidase (NEP) or neprilysin, a key enzyme for clearance of Aβ, is decreased in AD, the goal of the present study was to determine if NEP was also decreased in PA. We measured NEP immunoreactivity in frontal cortex of 12 AD and six PA cases and compared this with 10 normal (N) elderly individuals. None had any significant other pathology, and they were similar with respect to age, sex, and postmortem delay. In addition, Aβ1-40 and Aβ1-42 were measured by enzyme-linked immunosorbent assay (ELISA), whereas tau, synaptophysin, and α-synuclein were measured on Western blots. The AD cases had more neuritic plaques, neurofibrillary tangles, higher Braak stage, and more tau immunoreactivity in frontal cortex than both PA and N. In contrast, both PA and AD had more senile plaques and Aβ1-42 than N. NEP immunoreactivity was decreased in AD but not in PA. The decrease was unlikely the result of neuronal or synaptic loss because NEP immunoreactivity in frontotemporal degeneration with comparable degrees of synaptic loss as the AD cases was not different from control subjects. Although NEP enzyme activity was decreased in approximately half the AD cases, on average, it was not decreased compared with N or PA. The results add further evidence that PA is distinct from AD and indicate that decreased Aβ degradation by NEP is unlikely to contribute significantly to amyloid deposition in PA or, in many cases, of AD.

KW - Alzheimer disease

KW - Amyloid

KW - Neprilysin

KW - Neurofibrillary tangles

KW - Pathological aging

KW - Senile plaques

KW - Synaptic markers

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=20944435413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944435413&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 378

EP - 385

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 5

ER -